Deutsches Rotes Kreuz Gemeinnuetzige Krankenhaus GmbH Sachsen
- Address
- lock Available on a paid plan
Dermatology and Skin and Connective Tissue Diseases
The Deutsches Rotes Kreuz Gemeinnuetzige Krankenhaus GmbH Sachsen in Chemnitz is involved in clinical research focused on atopic dermatitis within the broader field of dermatology. The studies at this hospital are centered on understanding and improving care for inflammatory skin conditions, with an emphasis on evaluating new treatment options for patients.
- Research on atopic dermatitis, a chronic inflammatory skin disease
- Clinical evaluation of new therapies aimed at improving symptom control and patient outcomes
- Focused work in skin and connective tissue diseases at a hospital-based site
With a small but targeted trial portfolio, the site contributes to advancing treatment strategies in dermatology and supports the search for better options for people living with persistent skin disease.
Atopic Dermatitis Research
Clinical trial activity at this site is concentrated on atopic dermatitis, reflecting a clear interest in improving care for one of the most common chronic skin disorders. The research is designed to test new approaches that may help reduce itching, inflammation, and overall disease burden.
- Studies exploring treatment effectiveness in atopic dermatitis
- Investigation of potential new therapies for chronic inflammatory skin disease
- Patient-focused research aimed at better management of everyday symptoms
This work at Deutsches Rotes Kreuz Gemeinnuetzige Krankenhaus GmbH Sachsen adds to ongoing efforts to develop more effective and better-tolerated options for people affected by long-term skin inflammation.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 6 therapeutic areas and 6 of 7 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 3 by active trials.
- 1F. Hoffmann-La Roche AG1active
lock +2 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1F. Hoffmann-La Roche AG2trials
lock +2 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Deutsches Rotes Kreuz Gemeinnuetzige Krankenhaus GmbH Sachsen
lock Showing 1 of 12 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Deucravacitinib in Participants with Active Systemic Lupus Erythematosus (SLE) (POETYK SLE-1) | Bristol-Myers Squibb Services Unlimited Company | Phase III | Not Recruiting | May 2023 | — |
IMP list
lock Showing 1 of 7 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Dazodalibep | 3 | Unknown | 2024-06-07 | 2025-05-16 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.